RecruitingNCT06070961

Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance

Sponsor

Fondazione Italiana Linfomi - ETS

Enrollment

56 participants

Start Date

May 7, 2024

Study Type

OBSERVATIONAL

Conditions

Follicular Lymphoma

Summary

This is a prospective biological study evaluating the persistence of COVID-19 vaccine and other vaccines' (zoster, diphtheria and tetanus)-induced immunity in a subgroup patient affected by Follicular Lymphoma requiring treatment undergoing frontline induction immuno-chemotherapy and anti-CD20 maintenance within the prospective FIL\_FOLL19 study (NCT05058404). Blood samples from patients will be collected before and at planned timepoints during treatment to evaluate humoral and cellular immunity against SARS-COV-2, VZV, tetanus and diphtheria and T-cell markers characterization.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Enrolment in FIL\_FOLL19 study
Previous vaccination for COVID-19 (at least 3 doses)
Availability of informations about COVID-19 and other vaccines previously administered (vaccination records)
Willingness to comply with blood collection timepoints required for vaccination immunity evaluation
Signature of specific informed consent form

Exclusion Criteria1

None

Interventions

DIAGNOSTIC_TESTHumoral immunity vs Varicella Zoster Virus

Evaluation of humoral immunity vs VZV by ELISA (VZV gE-binding IgG)

DIAGNOSTIC_TESTCellular immunity vs SARS-CoV-2

Evaluation of cellular immunity vs SARS-CoV-2 by ELISpot assay

DIAGNOSTIC_TESTHumoral immunity vs SARS-CoV-2

Evaluation of Humoral immunity vs SARS-CoV-2 by ELISA assay (IgG anti-RBD and anti-N)

DIAGNOSTIC_TESTCellular immunity vs Varicella Zoster Virus

Evaluation of cellular immunity vs VZV by Enzyme-Linked immunoSPOT (ELISPOT) assay

DIAGNOSTIC_TESTDiphtheria toxin-binding IgG

Evaluation of diphtheria toxin-binding IgG by ELISA assay

DIAGNOSTIC_TESTTetanus toxoid-binding IgG

Evaluation of tetanus toxoid-binding IgG by ELISA assay

DIAGNOSTIC_TESTT-cell populations and markers characterization

Characterization of T-cell populations and markers by flow cytometry

Locations(14)

Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico

Avellino, AV, Italy

A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia

Alessandria, IT, Italy

Nuovo Ospedale degli Infermi, SSD Ematologia

Biella, IT, Italy

ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia

Milan, IT, Italy

Ospedale Maggiore Policlinico Fondazione IRCCS Ca' Granda - Ematologia

Milan, IT, Italy

A.O.U. Maggiore della Carità di Novara - S.C.D.U. Ematologia

Novara, IT, Italy

IRCCS Policlinico San Matteo - Divisione di Ematologia

Pavia, IT, Italy

Ospedale Guglielmo da Saliceto - U.O. Ematologia

Piacenza, IT, Italy

A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia U

Torino, IT, Italy

A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia

Torino, IT, Italy

ASST Spedali Civili - S.C. Ematologia

Brescia, Italy

Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia

Florence, Italy

Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia

Reggio Emilia, Italy

A.O.U. Senese - U.O.C. Ematologia

Siena, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06070961

Related Trials

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686174 locations